FDA Approves Mitapivat for Anemia in Thalassemia Patients 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
SAN FRANCISCO, Nov. 09, 2016 -- Invuity, Inc. (NASDAQ:IVTY), a leading surgical photonics company, today announced that company management is scheduled to present at the following upcoming investor conferences:
- The Stifel Healthcare Conference on Tuesday, November 15, 2016 at 11:45 a.m. ET in New York City.
- The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at 3:30 p.m. ET in New York City
A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company's website at www.invuity.com under Investors & Media. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 30 days following the presentation.
About Invuity®
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
CONTACT: Company Contact: Jim Mackaness Chief Financial Officer Invuity, Inc. 415-655-2129 Investors: Mark Klausner Westwicke Partners 443-213-0501 [email protected]
